Science Intelligence and InfoPros

Little things about Scientitic Watch and Information Professionnals

Posts Tagged ‘Open innovation

Open innovation, citizen scientists and crowdsourcing

leave a comment »

Science magazine Scientific American and InnoCentive, Inc., the global leader in open innovation, crowdsourcing, and prize competitions, have announced a partnership for an online hub that seeks to help science enthusiasts solve global scientific problems. The Scientific American Open Innovation Pavilion, scheduled to go live in the spring of 2013, will be jointly hosted on InnoCentive.comand ScientificAmerican.com.
Commercial organisations, government agencies, and non-profits (known as ‘Seekers’) will be able to post ‘Challenges’ on the Scientific American Open Innovation Pavilion. These ‘Challenges’ are well-articulated descriptions of scientific and technical problems that require innovative solutions. The Scientific American Open Innovation Pavilion provides these ‘Seekers’ with unprecedented access to a global pool of problem solvers, including InnoCentive’s existing 275,000-person-strong solver network and Scientific American’s audience of nearly five million monthly visitors to ScientificAmerican.com.

This partnership also marks the growth of InnoCentive’s collaboration with Nature Publishing Group (NPG), Scientific American’s parent organisation. In June 2009, InnoCentive and NPG launched the nature.com Open Innovation Pavilion, which is hosted on InnoCentive.com and nature.com, www.nature.com/openinnovation.

Advertisements

Written by hbasset

December 13, 2012 at 8:33 pm

Posted in Uncategorized

Tagged with

After Big Pharma, welcome to Open Pharma

leave a comment »

It seems that Open Pharma is really gaining momentum in the industry, even with Big Pharma. Every week sees news showing Open innovation initiatives…

Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort. The new Investigator Databank, established as part of this novel industry collaboration, will serve as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed.   This will allow participating pharmaceutical companies to reduce  time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites.  ”

Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank. Drugs.com, 15 November 2012. Available from: http://www.drugs.com/news/janssen-research-amp-development-announces-establishment-global-cross-pharmaceutical-clinical-trial-41551.html

 

Written by hbasset

November 21, 2012 at 8:29 pm

To read: Open Innovation, Social network and advances in Drug discovery

leave a comment »

Extract of a recent good review:

Social networking is beginning to make an impact on the drug discovery process. A convergence of different commercial and publicly accessible chemical informatics, databases and social networking tools is positioned to change the way that scientific and medical collaborations are initiated, maintained and expanded, particularly in the realm of complex, rare and orphan diseases . A community-based platform that combines traditional drug discovery informatics with Web 2.0 platforms and strong privacy is believed to be the key to facilitate richer and instantaneous collaborations involving health care professionals with the same interests.  This way data from differential diagnosis, experiments and new drugs being tested are archived, mined and then selectively shared between colleagues in the Internet with standardized formats.

New drugs are subject to exhaustive crucial scrutiny, yet there has never been a corresponding effort to collect reports of drugs delivering unexpected benefits. If open innovation can lead to the creation of the world’s most complete encyclopedia such as Wikipedia, that same approach could be used to capture the exceptional untapped value associated with existing drugs, and to power the discovery of important new medicines. In the Facebook and Google era, there might be a better, more efficient and systematic way of harnessing this communal wisdom for drug discovery.  (…)

In light of these initiatives, large pharmaceutical organizations are in the process of transitioning from a fully integrated pharmaceutical company to fully integrated pharmaceutical networks with a social networking component connecting members with similar interests as well as project tracking and planning.

Academic and private sectors need user-friendly and efficient tools for information exchange and to share data points from patients. Pharmaceutical companies have interdepartmental databases of patients and samples for research, clinical trials and for patient follow-up, but there is no communication between these databases, even within databases housed in the same company [Social Media in Science and Medicine: http://www.laboratory-journal.com/science/information-technology-it/social-media-science-and-medicine%5D. To date, there are no social networks in the market that offers useful solutions for science and medicine in the clinical genetics field [Social Media in Science and Medicine: http://www.laboratory-journal.com/science/information-technology-it/social-media-science-and-medicine%5D. It is paramount for physicians to have reliable tools that will facilitate diagnosis and identify better treatments for diseases. (…)

As in the medical field, there is an increasing need for solutions in the scientific field for networking and communication between professionals with common interests. ResearchGate, Academia.edu and Mendeley are already providing some tools to achieve this goal but more specialized open-source media tools are needed in science and medicine. Despite existing competition in science, the best way for science to have a major impact in society and change the way we approach diseases is through collaboration and networking. In the end, the outcome will be the development of better drugs and faster translation of basic science to the patient’s bedside”.

Fabricio F. Costa. Social networks, web-based tools and diseases: implications for biomedical research. Drug Discovery Today, Available online 23 October 2012 http://dx.doi.org/10.1016/j.drudis.2012.10.006

Written by hbasset

October 31, 2012 at 8:34 pm